



I DIALOGHI SUL DIABETE  
Diabetes Academy of Excellence 2015:  
Working together to shape the future of diabetes care

PIANO FORMATIVO 2015 – PROVIDER: FENIX ID 331

<b><u>METODOLOGIA</u></b>	Corso residenziale
<b><u>DATA INIZIO</u></b>	23 ottobre 2015
<b><u>SEDE</u></b>	Area EXPO Nuovo Polo Fieristico Via Carlo Pisacane, 1 20016 Pero
<b><u>DATA FINE</u></b>	24 ottobre 2015
<b><u>SEDE</u></b>	Atahotel EXPO Fiera Via Keplero 12 20016 Pero (MI)

**RAZIONALE**

Il diabete mellito di tipo 2 è una malattia metabolica che costituisce circa il 90% dei casi di diabete, riconosciuto dall'Organizzazione Mondiale della Sanità come epidemia globale. Le sue complicanze croniche come l'aumentato rischio di patologie cardiovascolari, di arteriopatie periferiche, neuropatie, cecità e insufficienza renale causano un elevato numero di disabilità e decessi, riducendo sia l'aspettativa sia la qualità della vita. Il diabete mellito rappresenta quindi un pesante carico economico e sociale.

Nonostante la disponibilità di farmaci efficaci, tuttavia, il numero di pazienti diabetici che non viene trattato precocemente e che non raggiunge i target glicemici raccomandati continua ad essere elevato.

La sfida principale nella gestione del diabete mellito è quella di poter raggiungere rapidamente i target terapeutici a fronte di minori effetti collaterali, attraverso un approccio il più possibile multidisciplinare e nel rispetto della qualità di vita del paziente.

L'accresciuta conoscenza sulla patogenesi del diabete mellito di tipo 2, incluso il controllo post-prandiale dell'omeostasi glicemica, ha portato allo sviluppo di nuove strategie terapeutiche tra cui quelle mirate a ad agire sul sistema incretinico.

Le terapie basate sulle incretine (inibitori del DPP-4 e analoghi del GLP-1) sono terapie anti-diabetiche di ultima generazione efficaci sul controllo della glicemia, riducendo il rischio di episodi ipoglicemici o incrementi del peso corporeo nel corso del trattamento.

La recente pubblicazione di importanti studi clinici nati per valutare la sicurezza sul versante cardiovascolare delle terapie basate di incretine, ne hanno sottolineato la neutralità.

Alla luce della disponibilità di queste nuove classi di farmaci, è importante una revisione della letteratura ed una condivisione delle esperienze volte alla individuazione di percorsi decisionali da condividere con i partecipanti.

### **OBIETTIVO GENERALE DELL'EVENTO**

Gli obiettivi dell'incontro sono:

1. Valutare il razionale fisiopatologico del trattamento con inibitori del DPP-4
2. Valutare l'approccio multidisciplinare al trattamento precoce
3. Valutare gli aspetti relativi alla sicurezza
4. Confrontare le esperienze dei partecipanti sull'uso di questi nuovi farmaci
5. Fornire un aggiornamento scientifico sulle formulazioni di più recente introduzione

### **OBIETTIVO FORMATIVO (di processo)**

DOCUMENTAZIONE CLINICA. PERCORSI CLINICO-ASSISTENZIALI DIAGNOSTICI E RIABILITATIVI, PROFILI DI ASSISTENZA – PROFILI DI CURA

### **PROFESSIONI**

La tipologia del target è:

**Medico Chirurgo:** Nefrologia – Cardiologia - Medicina Interna – Malattie metaboliche e Diabetologia – Endocrinologia - Geriatria

**PARTECIPANTI PREVISTI** n. 100

### **DURATA EFFETTIVA DELL'ATTIVITA' FORMATIVA**

L'impegno globale previsto per ogni discente è di 14 ore.

### **N. CREDITI**

Numero crediti ECM → 15,5 (3 ore di formazione interattiva)

### **INFORMAZIONI**

I crediti saranno rilasciati ai partecipanti che avranno partecipato a tutte le sessioni e che abbiano risposto adeguatamente al test finale.

## **PROGRAMMA**

Programma							
Milano, 23 ottobre 2015							
Dalle ore	Alle ore	Titolo della Relazione	Min Frontale	Min Interattiva	Min NO ECM		Relatore
<b>10.30</b>	<b>11.00</b>	<b>WELCOME AND INTRODUCTION</b> - Housekeeping including format of symposium - Introduction to speakers and overview of agenda	<b>0.30</b>			Serie di relazioni su tema preordinato	Stefano Genovese - Marc Evans
		<i>Benvenuto ed introduzione</i>					
<b>11.00</b>	<b>12.10</b>	<b>2015 EASD/ADA GUIDELINES FOR MANAGEMENT OF HYPERGLYCAEMIA IN TYPE 2 DIABETES (T2D): A PATIENT-CENTRED APPROACH</b> - Moving away from general treatment algorithms towards individualised treatment of diabetes - The impact of starting diabetes treatment early; examining the trends - Comprehensive cardiovascular (CV) risk reduction as a major focus of diabetes treatment	<b>1.10</b>			Lezioni magistrali	Stefano Genovese
		<i>Linee guida EASD/ADA 2015 per la gestione dell'iperglicemia nel diabete di tipo 2: un approccio centrato sul paziente</i>					
<b>12.10</b>	<b>13.10</b>	<b>LUNCH</b>			<b>1.00</b>		
<b>13.10</b>	<b>14.20</b>	<b>ARE ALL DPP-4 INHIBITORS THE SAME? THE RATIONALE FOR A NEW DPP-4 INHIBITOR</b> - Overview of the DPP-4 inhibitor class and its members - Sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin - The main differentiating factors and unique properties of alogliptin vs the rest of the DPP-4 inhibitor class	<b>1.10</b>			Lezioni magistrali	Jørgen Rungby
		<i>Gli inibitori del DPP-4 sono tutti uguali? Le ragioni per un nuovo DPP-4 inibitore.</i>					

14.20	15.50	<p><b>DEBATING THE OPTIMAL MANAGEMENT OF POST-ACS T2D PATIENTS</b></p> <p>The cardiologist's perspective The diabetologist's perspective</p> <ul style="list-style-type: none"> <li>- Who manages these patients?</li> <li>- What considerations are made relating to T2D?</li> <li>- What considerations are made relating to CV risk?</li> <li>- Are post-ACS T2D patients managed differently?</li> <li>- What are the biggest challenges in this population?</li> </ul>	1.30			Tavole rotonde con dibattito tra esperti	Edoardo Gronda - Jean-François Yale
		<i>Confronto sulla gestione ottimale del paziente con DM2 dopo un episodio di sindrome coronarica acuta</i>					
15.50	17.20	<p><b>WHERE DOES ACUTE CORONARY SYNDROME (ACS) FIT IN THE T2D PATIENT JOURNEY? EXPLORING THE EVIDENCE FROM RECENT CV OUTCOMES STUDIES</b></p> <ul style="list-style-type: none"> <li>- Provide an introduction to the epidemiology of ACS</li> <li>- Understand how patients are managed in the acute setting and over the long term</li> <li>- What do the guidelines say?</li> <li>- Summary of the historical trials: UKPDS, ACCORD, ADVANCE, VADT</li> <li>FDA requirement since 2008 for CV safety studies during development of diabetes drugs - Briefly mention rosiglitazone as a factor in the FDA requirement</li> <li>- Review of patient population and CV safety data from SAVOR-TIMI, EXAMINE and TECOS</li> <li>- [Possibly include ELIXA depending on data presented at ADA]</li> </ul>	1.30			Lezioni magistrali	Edoardo Gronda - Marc Evans
		<i>Quali conseguenze ha la sindrome coronarica acuta sulla vita di un paziente con DM2? Revisione degli studi recenti</i>					
17.20	18.50	<p><b>Q&amp;A SESSION WITH THE DELEGATES</b></p> <ul style="list-style-type: none"> <li>- Opportunity for panel to take questions from the delegates (facilitated by Chairs)</li> <li>- Chairs to also direct their own questions to the panel</li> <li>- Back-up questions to be developed</li> </ul>	1.30			Confronto/dibattito tra pubblico ed esperto/i guidato da un conduttore	All, facilitated by Stefano Genovese - Marc Evans
		<i>Confronto e dibattito con i partecipanti sui</i>					

		<i>temi sopra trattati</i>					
18.50	19.10	SUMMARY OF DAY'S PROCEEDINGS AND CLOSE OF DAY 1	0.20			Serie di relazioni su tema preordinato	Stefano Genovese - Marc Evans
		<i>Conclusioni e chiusura dei lavori della giornata</i>					
Totale ore ECM Frontale			7.10				
Totale ore ECM Interattiva				0.00			
Totale ore non ECM						1.00	

Programma							
Milano, 24 ottobre 2015							
Dalle ore	Alle ore	Titolo della Relazione	Min Frontale	Min Interattiva	Min NO ECM		Relatore
8.30	8.50	INTRODUCTION TO DAY 2	0.20			Serie di relazioni su tema preordinato	Stefano Genovese - Marc Evans
		<i>Introduzione</i>					
8.50	10.10	<b>THE UNDERESTIMATED BURDEN OF HYPOGLYCAEMIA IN T2D</b> Review of the physiological effects of glucose imbalance Defining hypoglycaemia Review of the clinical effects of hypoglycaemia What glucose fluctuations mean for the patient (impact on quality of life) Identifying patients at risk of hypoglycaemia	1.20			Lezioni magistrali	Brian Frier
		<i>L'ipoglicemia nel DM2: un problema sottostimato</i>					
10.10	11.30	<b>INSULIN RESISTANCE: CORE DEFECT IN T2D AND IMPLICATIONS FOR CV DISEASE</b> - What is pre-diabetes? - What is impaired fasting glucose? - What is impaired glucose tolerance? - The roles of these conditions in the development of T2D - The role of insulin resistance in the development of CV complications	1.20			Lezioni magistrali	Angelo Avogaro

		<i>L'insulinoresistenza: problematiche principali nel DM2 e implicazioni nella patologia cardiovascolare</i>					
11.30	12.30	<b>COMBINING ALOGLIPTIN AND PIOGLITAZONE: A SYNERGISTIC TREATMENT APPROACH</b> - The pathophysiological evidence - The clinical evidence	1.00			Lezioni magistrali	Guntram Schernthanner
		<i>Il trattamento con associazione alogliptin e pioglitazone: un approccio sinergico</i>					
12.30	13.30	<b>LUNCH</b>			1.00		
13.30	16.30	<b>PATIENT-CENTRED MANAGEMENT OF T2D: WHAT DOES IT MEAN IN PRACTICE?</b> A series of interactive case study 'workshops' A total of 8 standardised T2D patient case studies to illustrate how to consider individualising therapy in high-risk patient populations (eg managing T2D in post-ACS patients; managing T2D in chronic kidney disease patients) The delegates will be asked to vote on which treatment option they would use for each case, which will be done using live iPad or keypad voting Vote results for case studies to be collated, presented and discussed		3.00		Presentazione di problemi o di casi clinici in seduta plenaria	All, facilitated by Stefano Genovese - Marc Evans
		<i>La gestione del DM2 centrato sul paziente: cosa significa nella pratica clinica? - Presentazione di casi clinici interattivi</i>					
16.30	16.40	<b>SUMMARY OF DAY 2 AND MEETING CLOSE</b>	0.10			Confronto/dibattito tra pubblico ed esperto/i guidato da un conduttore	Stefano Genovese - Marc Evans
		<i>Conclusioni e chiusura dell'evento</i>					
16.40	16.50	<b>CME questionnaire - Quality and satisfaction evaluation forms</b>			0.10		
		<i>Questionario ECM - Questionari di valutazione e soddisfazione</i>					
<b>Totale ore ECM Frontale</b>			<b>4.10</b>				
<b>Totale ore ECM Interattiva</b>				<b>3.00</b>			
<b>Totale ore non ECM</b>					<b>1.10</b>		

## **RESPONSABILI SCIENTIFICI**

### **Lyndon Marc Evans**

Consultant Diabetologist  
University Hospital Llandough, Penlan Road – Cardiff – Wales, UK

### **Stefano Genovese**

Director of Diabetes and Metabolic Diseases  
Unit Cardiovascular and Metabolic Department  
Multimedica Group - Sesto San Giovanni (MI), IT

## **DOCENTI (qualifica professionale)**

### **Angelo Avogaro**

Full Professor of Diabetes and Metabolic Diseases  
Chief Physician, Department Endocrinology and Metabolic Diseases  
Padova University Hospital - Padova, IT

### **Lyndon Marc Evans**

Consultant Diabetologist  
University Hospital Llandough, Penlan Road – Cardiff – Wales, UK

### **Brian Murray Frier**

Honorary Professor of Diabetes  
BHF Centre for Cardiovascular Science  
The Queen's Medical Research Institute - Edinburgh - Scotland, UK

### **Stefano Genovese**

Director of Diabetes and Metabolic Diseases  
Unit Cardiovascular and Metabolic Department  
Multimedica Group - Sesto San Giovanni (MI), IT

### **Jean François Yale**

Professor in the Department of Medicine and Nutrition and Food Science Centre  
McGill University, Medical Department – Montreal – Quebec, CAN

### **Edoardo Gronda**

Expert in Care of complex patients with Cardiac Insufficiency  
Director of Cardiology Division  
IRCCS Multimedica, Sesto San Giovanni (MI)

### **Jørgen Rungby**

Chief Physician, Dept. Endocrinology and Centre for Diabetes Research  
Gentofte University Hospital - Copenhagen, DK.  
Professor of Clinical Pharmacology - University of Aarhus, DK

**Guntram Schernthaner**

Professor of Medicine,  
Medical University of Vienna – AU

**Nel caso di improvviso e imprevedibile evento che determinasse l'impossibilità di un docente a presenziare, uno dei restanti docenti, potrà effettuare la relazione in qualità di sostituto (previa rivalutazione del CV da parte del Responsabile Scientifico in considerazione dei contenuti della relazione/docenza)**

**SEGRETERIA ORGANIZZATIVA**

Fenix Srl  
Via Ugo Foscolo, 25 - 27100 Pavia  
Tel 0382 1752851 - Fax 0382 1752852  
e-mail: [info@fenix-srl.it](mailto:info@fenix-srl.it)  
Responsabile dr. Agostino Tacconi



## CURRICULA

### Angelo Avogaro

FORMATO EUROPEO  
PER IL CURRICULUM  
VITAE



#### INFORMAZIONI PERSONALI

Nome Angelo Avogaro  
Indirizzo Dorsoduro 3455, 30123 Venezia  
Telefono 0415240201  
Fax 0498754179  
E-mail [angelo.avogaro@unipd.it](mailto:angelo.avogaro@unipd.it)  
Nazionalità Italiana

Data di nascita 21 marzo 1955

#### ESPERIENZA LAVORATIVA

- Date (da – a) 01-11-2001 ad oggi
- Nome e indirizzo del datore di lavoro Università degli Studi di Padova
- Tipo di azienda o settore
- Tipo di impiego Professore Ordinario di Endocrinologia e Metabolismo
- Principali mansioni e responsabilità Responsabile di U.O.C. di Malattie del Metabolismo e servizio aggregato di Diabetologia Azienda Ospedaliera di Padova
- Principali materie / abilità professionali oggetto dello studio Specializzazione in Malattie del Ricambio e Medicina Interna
- Qualifica conseguita

ALTRE CAPACITÀ E COMPETENZE  
*Competenze non  
precedentemente indicate.*

Membro del Review Committee and Programme Board Meeting della European Foundation for the Study of Diabetes.  
Membro dell' Editorial Board di JACC  
membro dell' Editorial Board del Journal of Diabetes and its Complications  
Membro dell' Editorial Board di Diabetes Care  
Membro dell' Editorial Board di Diabetes, Obesity & Metabolism  
Senior Editor di Diabetes & Nutrition  
Membro del Consiglio Direttivo della Società Italiana di Endocrinologia  
Dal 2001 Principal Investigator in numerosi studi di fase 3 e 4.

Reviewer per le seguenti riviste internazionali:

-Diabetologia, Diabetes, Nutrition and Metabolism, Acta Endocrinologica, Diabetes, European Journal of Clinical Investigation, Giornale Italiano di Cardiologia, Drugs, Journal of Endocrinological Investigation, Diabetes Care, International Journal of Obesity, American Journal of Physiology, Journal of Hypertension, JACC, Journal of the Clinical Endocrinology & Metabolism, Pharmacological Research, Arteriosclerosis Thrombosis and Vascular Biology, Kidney International, European Journal of Endocrinology, Circulation, International Journal of Cardiology, International Journal of Cancer  
Top reviewer per Diabetes Care 2012

Ho servito come reviewer per le seguenti istituzioni:

Diabetes UK,  
United States-Israel Binational Science Foundation  
Swiss Research Foundation  
Dutch Diabetes research Foundation  
European Foundation for the Study of Diabetes

H index Web of Science: 46

15/11/2014



Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base al D. Lgs. 196 del 30 giugno 2003"

# Lyndon Marc Evans

## PERSONAL INFORMATION

Lyndon Marc Evans 

 University Hospital Llandough, Cardiff

 [Marclyndon1@hotmail.com](mailto:Marclyndon1@hotmail.com)

Sex Male | Nationality British

POSITION **Consultant Diabetologist**

## WORK EXPERIENCE

Replace with dates (from - to)

**Consultant Diabetologist**

University Hospital Llandough, Penlan Road, Cardiff, CF64 2XX

Healthcare sector

**PhD thesis supervisor**

The effects of PPAR-gamma modulation on immunomodulation and calcium signalling – N Singh (University of Wales Institute Cardiff, 2006)

**MD thesis Supervisor**

1. The effects of insulin sensitizing therapy on heart muscle function in patients with type 2 diabetes. AW Roberts (University of Wales college of Medicine, 2007)
2. The Effects of Insulin Sensitizing Therapy on Platelet, Vascular Function and Blood Pressure in Type 2 Diabetes Mellitus. M Khanoukhar (2008)
3. The metabolic and vascular effects of conjugated linoleic acid H. Boulasani (2008)

Higher Education sector

Reviewer for a variety of journals

Reviewer for various national and international grant awarding bodies

Editor in chief of Diabetes Therapy

## EDUCATION AND TRAINING

Qualifications **MB Bch MRCP (UK), MD (Wales)**



## ADDITIONAL INFORMATION

### Research Interest

- Field of health economics
- Assessing the relationships between hypoglycaemia, weight gain, cost effectiveness and quality of life in patients with type 2 diabetes

### Current research projects

- Understanding the cost effectiveness of self-glucose monitoring in relation to insulin regimens in UK clinical practice
- Evaluating willingness to pay – The value of flexibility
- Assessing the effect of hypoglycaemia on quality of life
- Quantifying the resource implications, morbidity and mortality associated with hypoglycaemia in routine UK clinical practice.
- Evaluating the role of incretin based therapies in routine primary care
- Assessing the economic value of achieving glucose control targets in routine clinical practice – The impact of weight and hypoglycaemia on value for money
- Quantifying the cost of severe and non-severe hypoglycaemia

## ANNEXES

### Publications

We need a diabetes complications trial in the UK. LM Evans, CJ Currie. Diabetic medicine 1997; 14:168-70

Ratio of inhaled corticosteroid to bronchodilator as an indicator of quality of asthma prescribing. BMJ 1997;314: 680. Currie CJ, LM Evans, Morgan CL.

Mental health may deteriorate as a result of induced abortion. C LI Morgan, LM Evans, CJ Currie, JR Peters. BMJ.1997. 314: 902.

The current status of hormone replacement therapy in coronary heart disease prevention. LM Evans. Current opinion in lipidology.1997 8 (4): 221-2.

Cardiovascular disease in Women. LM Evans. Current opinion in lipidology 1998 9: (3) 99 – 101

Pituitary apoplexy following combination chemotherapy. JS Davies, DAE Rees, LM Evans, MF Scanlon. Endocrine related cancer. 1998. 5 151-3.

Endothelial dysfunction in hypopituitary patients with adult growth hormone deficiency (GHD). LM Evans, JS Davies, A Rees, MF Scanlon. Clinical Endocrinology 1999. 50: 457 – 464.

Peripheral Haemodynamics in Acromegaly: The role of endothelial dysfunction. LM Evans,JS Davies. Clinical Endocrinology 1998, 49 (6): 7-11

Growth hormone replacement therapy restores endothelial function and reduces oxidative stress in adult growth hormone deficient patients. LM Evans, RA Anderson, JS Davies, MP Frennaux, MJ Lewis, SK Jackson, A Rees, MF Scanlon. European Journal of Endocrinology 2000, 142: 254 – 262



A therapeutic assessment with growth hormone replacement therapy in hypopituitary adults and its influence upon continued prescription by general practitioners. JS Davies, K Obuobie, J Smith, DA Rees, A Furlong, N Davies, LM Evans, MF Scanlon. *Clinical Endocrinology* 2000; 52 (3): 295 – 304.

Growth hormone replacement therapy and endothelial dysfunction in hypopituitary patients with growth hormone deficiency. *Journal of Clinical Endocrinology and Metabolism*. JC Smith, LM Evans, JS Davies. 1999, 84: 4749 – 50

Ciprofibrate therapy improves endothelial function and reduces post-prandial lipaemia and oxidative stress in type 2 diabetes. LM Evans, RA Anderson, GR Ellis, SK Jackson, MP Frenneaux, K Morris, J Graham, MJ Lewis, S Davies, A Rees. *Circulation* 2000 101: 1773 – 9

Diabetic dyslipidaemia and coronary heart disease: A new perspective. LM Evans, N Khan, A Rees. *Current Opinion in Lipidology*. 1999. 10 (5): 387 – 391

LM Evans, A Rees. Diabetic dyslipidaemia. Chapter 10 in *Lipids and atherosclerosis annual*. 2001 (Martin Dunitz) Ed. A Gaw & J Shepherd

A Therapeutic trial hormone in hypopituitary adults and its influence upon continued prescription by general practitioners. Davies JS, Obuobie K, Smith J, Rees DA, Furlong A, Davies N, Evans LM, Scanlon MF. *Clin Endocrinol*. 2000 Mar;52(3):295-303

Triple H Syndrome – A novel autoimmune endocrinopathy. *Journal of Clinical Endocrinology and Metabolism*. 2000. 85: 2644 – 8. S Farouq, LM Evans, MK Jones, S' O Rahilly.

Cancrum oris occurring in a caucasian male with well controlled type 2 diabetes – A novel oral complication of diabetes. LM Evans, H Lane, MK Jones. *Diabetic Medicine*. 2001 (17): 246 – 8.

Post-prandial lipaemia is associated with increased oxidative stress and endothelial dysfunction in healthy subjects and is augmented in non-insulin dependent diabetes. RA Anderson, LM Evans, GR Ellis, JA Morris-Thorgood, SK Jackson, MJ Lewis, A Rees, MP Frenneaux. *Atherosclerosis* 2001; 154: 475 – 483

Cholestrol reduction and the acute coronary syndrome. LM Evans, P Owen, A Ogunko. *Current Opinion in lipidology* 2001 (12): 367 – 9.

The Effects of Induced Hypogonadism on Arterial Stiffness, Body Composition and Metabolic Parameters in Males with Prostate Cancer JC Smith, S Bennett, LM Evans, HG Kynaston, M Parmar, MD Mason, JR Cockcroft, MF Scanlon, JS Davies. *J Clin Endo & Metab*. 2001. 86: 4261 – 7

Statin associated myotoxicity – A Review. Evans M, Rees A. *Curr Opin Lipidol*. 2002 Aug;13(4):415-20

Effects of HMG-Co A reductase inhibitors on skeletal muscle – Are all statins the same? *Drug Safety*. 2002;25(9):649-63.

The associations of the PRO-12-ALA mutation of the PPAR-gamma receptor gene with glycaemic control, obesity and dyslipidaemia in patients with type 2 diabetes. M Ahuwalia, LM Evans, K Morris, C Currie, JS Davies, A Rees, A Thomas. *Diabetes Obes Metab*. 2002 Nov;4(6):376-8.

The future of cholesterol lowering therapy. Evans M, Roberts AW, Rees A. *Current Opinion in Lipidology* 2002 Dec;13(6):663-9

Increased central arterial stiffness in hypothyroidism. Obuobie K, Smith J, Evans LM, John R, Davies JS, Lazarus JH. *J Clin Endocrinol Metab* 2002; 87(10):4662-6

The effects of insulin lispro and chronic vitamin C therapy on endothelial function, post-prandial lipaemia and oxidative stress in patients with type 2 diabetes. Evans LM, Anderson RA, Khan N, Morris K, Thomas AW, Dealy D, Frenneaux MP, Rees A. *Eur J Clin Invest* 2003;33(3):231-8.

The effect of PPAR-gamma agonists on thyroid eye disease. K Starkey, A Heufelder, LM Evans, JS

Davies, G Baker, M Ludgate. J Clin Endo & Metab 2003 Jan;88(1):55-9.

The TSH response to domperidone reflects the biological activity of prolactin in macroprolactinaemia and hyperprolactinaemia. Pinto L, Hanna F, Evans LM, et al. Clin Endocrinol (Oxf). 2003 Nov;59(5):580-4.

Increased central arterial stiffness in hypothyroidism. Obuobie K, Smith J, Evans LM, John R, Davies JS, Lazarus JH. J Clin Endocrinol Metab 2002; 87(10):4662-6

The effects of depot long-acting somatostatin analog on central aortic pressure and arterial stiffness in acromegaly. Smith JC, Lane H, Davies N, Evans LM, Cockcroft J, Scanlon MF, Davies JS. J Clin Endocrinol Metab. 2003;88(6):2556-61

Endothelial function and coagulant factors in growth hormone-treated hypopituitary adults receiving desmopressin. Smith JC, Lane HA, Lewis J, Dann S, Goodfellow J, Collins P, Evans LM, Scanlon MF, Davies JS. J Clin Endocrinol Metab. 2003;88(5):2152-6

Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Biswas M, Smith J, Jeadon D, Evans LM, et al. Clin Endocrinol (Oxf). 2005 Jul;63(1):26-31

Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. Roberts AW, Rees A, Thomas AW, Evans LM Curr Opin In Lipidol. 2003 Dec;14(6):567-73.

Medical lipid regulating therapy: Current evidence, ongoing trials and future developments. Evans M, Roberts A, Rees A. Drugs. 2004;64(11):1181-96.

The metabolic syndrome, inflammation and cardiovascular disease in type 2 diabetes. Roberts AW, Evans LM. Curr Opin Lipidol. 2004 Feb;15(1):89-91.

Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with Type 2 diabetes? Evans M, McEwan P, Rees A, Peters JR, Currie CJ. Diabetes Obes Metab. 2004 Jul;6(4):299-307

Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus Cockcroft FR, Wilkinson IB Evans LM et al. Am J Hypertens. 2005 Nov;18(11):1463-7

The PPAR-gamma activator, Rosiglitazone, inhibits actin polymerisation in monocytes: involvement of Akt and intracellular calcium Singh N, Webb R, Adams R, Evans LM. Biochem Biophys Res Commun. 2005 Jul 29;333(2):455-62

Platelet nitrate responsiveness in fasting and postprandial type 2 diabetes Anderson RA, Ellis GR, Evans LM et al. Diab Vasc Dis Res. 2005 May;2(2):88-93

Peripheral cytokine expression in autoimmune thyroiditis: effects of in vitro modulation by rosiglitazone and dexamethasone Okosieme B, Parkes A, Thomas AW, Evans LM, Lazarus J. Thyroid. 2006 Oct;16(10):953-60

A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies. Pharmacoeconomics. 2006;24 Suppl 1:5-19. Bagust A, Evans M, Beale S, Home PD, Perry AS, Stewart M

Patton C, Okosieme B, Evans LM. Dumping syndrome presenting three decades after vagotomy. N Z Med J. 2007 Nov 9;120(1265):U2807

Insulin resistance and inflammation – A further systemic complication of COPD. Bolton C, Evans LM, Inonescu AA, et al COPD 2007 (2): 121- 6

Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Creely SJ, McTernan PJ, Kusminski CM, Fisher M, Khanolkar M, Evans M, Hart AL, Kumar S. Am J Physiol Endocrinol Metab. 2007;292(3):E740-7.



Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom. *Cardiovasc Diabetol*. 2008 Aug 11;7:24. Woehl A, Evans M, Tetlow AP, McEwan P

Peter R, Cox A, Evans LM. Management of diabetes in cardiovascular patients: diabetic heart disease. *Heart*. 2008 Mar;94(3):369

Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus-An effect probably mediated by direct platelet PPARgamma activation Khanoulkar M, Morris RKH, Thomas AW, Evans LM. *Atherosclerosis*. 2008 Apr;197(2):718-24

Can admission and fasting glucose reliably identify undiagnosed diabetes in patients with acute coronary syndrome? *Diabetes Care*. 2008 Oct;31(10):1955-9 Okosieme OE, Peter R, Usman M, Bolusani H, Surullram P, George L, Evans LM

Association between dyslipidemia and vascular events in patients treated with statins: report from the UK General Practice Research Database *Atherosclerosis*. 2010 Jan; 208(1):210-6. Sazonov V, Beetsch J, Phatak H, Wentworth C, Evans M

Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. *Lancet*. 2010 Feb 6;375(9713):481-9. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, Zagar T, Poole CD

Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. *Diabetes Obes Metab*. 2010 May;12(5):431-6. McEwan P, Evans M, Kan H, Bergenheim K.

Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008. *Diabet Med*. 2010 Jul;27(7):744-52 Currie CJ, Peters JR, Evans M

A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes P. McEwan, M. Evans & K. Bergenheim. *Diabetes Obes Metab*. 2010;12(7):623-30

A longitudinal study into the new and long-term use of self-monitoring blood glucose strips in the UK. Morgan CL, Griffin A, Chamberlain GH, Turkiendorf A, McEwan P, Evans LM, Owens DR. *Diabetes Ther*. 2010 Aug;1(1):1-9.

Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. Evans M, Bain SC, Hogan S, Bilous RW; Collaborative Study Group participants. *Nephrol Dial Transplant*. 2012 Jun;27(6):2255-63. doi: 10.1093/ndt/gfr696. Epub 2011 Dec 15. PMID: 22172728

Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study. *Clin Ther*. 2011 Jan;33(1):27-35 Morgan CL, Evans M, Toff AD, Jenkins-Jones S, Poole CD, Currie CJ

A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. *Diabetes Obes Metab*. 2011 Aug;13(8):677-84. doi: 10.1111/j.1463-1326.2011.01395.x. Evans M, Schumm-Draeger PM, Vora J, King AB

Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. Morgan CL, Jenkins-Jones S, Evans M, Barnett AH, Poole CD, Currie CJ. *Diabetes Obes Metab*. 2012 May;14(5):424-32. doi: 10.1111/j.1463-1326.2011.01552.x

A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Evans M, McEwan P, O'Shea R, George L. *Diabetes Ther*. 2013 Jun;4(1):27-40. doi: 10.1007/s13300-012-0015-6. Epub 2012 Dec 8.



PMID: 23225378

The impact of treatment noncompliance on mortality in people with type 2 diabetes. Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, Burton CM, Evans M. *Diabetes Care*. 2012 Jun;35(6):1279-84.

The impact of treatment non-compliance on mortality in people with type 1 diabetes. Currie CJ, Peyrot M, Morgan CL, Poole CD, Jenkins-Jones S, Rubin RR, Burton CM, Evans M. *J Diabetes Complications*. 2013 May-Jun;27(3):219-23. doi: 10.1016/j.jdiacomp.2012.10.006. Epub 2012 Nov 13.

What Next after Metformin? A Retrospective Evaluation of the Outcome of Second-Line, Glucose-Lowering Therapies in People with Type 2 Diabetes. Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. *J Clin Endocrinol Metab*. 2012 Oct 17. [Epub ahead of print].

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective. Brown DX, Evans M. *J Nutr Metab*. 2012;2012:381713. doi: 10.1155/2012/381713

Linagliptin as add-on therapy for type 2 diabetes - an overview. Brown DX, Choudhury M, Evans M. *Drugs Today*. 2012 Oct;48(10):645-54. doi: 10.1358/dot.2012.48.10.1860771.

Lixisenatide as add-on therapy to basal insulin. Brown DX, Butler EL, Evans M. *Drug Des Devel Ther*. 2013 Dec 13;8:25-38. doi: 10.2147/DDDT.S45108. Review. PMID: 24363554

Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. Evans M, Jensen HH, Bøgelund M, Gundgaard J, Chubb B, Khunti K. *J Med Econ*. 2013 Nov;16(11):1357-65. doi: 10.3111/13696998.2013.846262. Epub 2013 Oct 11. PMID: 24111563

Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Evans M, Khunti K, Mamdani M, Galbo-Jørgensen CB, Gundgaard J, Bøgelund M, Harris S. *Health Qual Life Outcomes*. 2013 Jun 3;11:90. doi: 10.1186/1477-7525-11-90. PMID: 23731777

Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice—a case-based evaluation. Evans M, McEwan P, Foss V. *J Med Econ*. 2015 Feb;18(2):96-105. doi: 10.3111/13696998.2014.975234. Epub 2014 Oct 29. PMID: 25325179

Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration. McEwan P, Gordon J, Evans M, Ward T, Bennett H, Bergenheim K. *Med Decis Making*. 2015 Jan 16. pii: 0272989X14565821

Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. *J Med Econ*. 2015 Jan;18(1):56-68. doi: 10.3111/13696998.2014.971160.

Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective. Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. *Diabetes Obes Metab*. 2014 Apr;16(4):366-75. doi: 10.1111/dom.12250. Epub 2014 Jan 16. PMID: 24373113

Healthcare resource implications of hypoglycemia-related hospital admissions and inpatient hypoglycemia: retrospective record-linked cohort studies in England.





McEwan P, Larsen Thorsted B, Wolden M, Jacobsen J, Evans M.  
BMJ Open Diabetes Res Care. 2015 Mar 20;3(1):e000057. doi: 10.1136/bmjdr-2014-000057.  
eCollection 2015.

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease?  
Evans M, Dejager S, Schweizer A, Foley JE.  
Diabetes Ther. 2015 Mar;6(1):1-5. doi: 10.1007/s13300-015-0104-4. Epub 2015 Mar 18.

Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care.  
Nyeland ME, Ploug UJ, Richards A, Garcia Alvarez L, Demuth D, Muthutantri A, Skovgaard R, Evans M. Int J Clin Pract. 2015 Mar;69(3):281-91. doi: 10.1111/ijcp.12575. Epub 2014 Oct 10

Approach to assessing the economic impact of insulin-related hypoglycaemia using the novel Local Impact of Hypoglycaemia Tool.  
Parekh WA, Ashley D, Chubb B, Gillies H, Evans M.  
Diabet Med. 2015 Mar 28. doi: 10.1111/dme.12771. [Epub ahead of print]  
PMID: 25816891

Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice.  
Evans M, McEwan P. J Comp Eff Res. 2015 May 11:1-8

Clinical use of insulin degludec.  
Vora J, Cariou B, Evans M, Gross JL, Harris S, Landstedt-Hallin L, Mithal A, Rodriguez MR, Meneghini L. Diabetes Res Clin Pract. 2015 Jul;109(1):19-31. doi: 10.1016/j.diabres.2015.04.002.

A systematic review of the safety of incretin-based therapies in type 2 diabetes. Expert review of Endocrinology and metabolism (2015) (accepted). M Evans, SC Bain, J Vora.

## Abstracts

Apo(a) isoforms associated with changes in plasma Lp(a) concentrations following GH therapy in hypopituitary adults with growth hormone deficiency. JS Davies, R Morgan, LM Evans, A Rees, MF Scanlon. Endocrinology and metabolism 1997 (Suppl B): 158.

Coagulation factors in Adult hypopituitarism with growth hormone deficiency. JS Davies, LM Evans, A Rees, MF Scanlon. Journal of Endocrinology 1998; 156 (Suppl) : 250.

Enhanced oxidative stress in adult hypopituitary patients with growth hormone deficiency. RA Anderson, GR Ellis, LM Evans, JS Davies, MP Frenneaux, MJ Lewis, A Rees, MF Scanlon. Journal of Endocrinology 1998; (Suppl. 1): 156; P 24

Post-prandial lipaemia with the production of triglyceride rich lipoproteins results in enhanced oxidative stress and augmented endothelial dysfunction in non-insulin dependent diabetes. LM Evans, RA Anderson, GR Ellis, JS Davies, MJ Lewis, MP Frenneaux, SK Jackson, A Rees. Circulation 1998 (suppl) 220: 1004.

In healthy adults, post-prandial lipaemia results in triglyceride enrichment of very-low density lipoprotein, enhanced oxidative stress and deterioration in endothelial function. RA Anderson, LM Evans, GR Ellis, J Graham, SK Jackson, MJ Lewis, A Rees, M Frenneaux. Atherosclerosis. 1999 (145) 434.

Ciprofibrate reduces the post-prandial generation of triglyceride rich lipoproteins and attenuates the associated endothelial dysfunction and enhanced oxidative stress in non-insulin dependent diabetes mellitus. LM Evans, RA Anderson, JS Davies, GR Ellis, SK Jackson, J Graham, MJ Lewis, MP Frenneaux, A Rees. Atherosclerosis. 1999 (145) 434.

Growth hormone replacement therapy reverses endothelial dysfunction in hypopituitary adults with growth hormone deficiency (GHD). LM Evans, JS Davies, A Rees, MF Scanlon. Endocrine society, New Orleans, 1998. P221



Increased free radical release in hypopituitary adults with GHD. RA Anderson, GR Ellis, LM Evans, JS Davies, SK Jackson, MJ Lewis, MP Frenneaux. *Journal of Endocrinology* 1998. 156 (suppl): 24.

Ciprofibrate therapy blunts post-prandial lipaemia and attenuates free radical release in type 2 diabetes. LM Evans, RA Anderson, GR Ellis, SK Jackson, MJ Lewis, MP Frenneaux, A Rees. *Diabetes*. 1999. 48 (Suppl 1) A365.

Post-prandial lipaemia and endothelial dysfunction in healthy subjects and patients with non-insulin dependent diabetes. LM Evans, RA Anderson, JS Davies, A Rees. *Atherosclerosis* 1999 141 (1) 185.

Ciprofibrate therapy reduces post-prandial lipaemia and improves endothelial function in type 2 diabetes. LM Evans, RA Anderson, GR Ellis, SK Jackson, MJ Lewis, MP Frenneaux, A Rees. *Diabetes*. 1999 48 (Suppl 1) A131.

Comparison of the subcutaneous absorption of HOE 901 and NPH human insulin in type 2 diabetic subjects. SD Luzio, DR Owens, LM Evans, AG Ogunko, P Beck, R Kurzhals. (Abstract). *Diabetes*. 1999 48 (Suppl 1). A111

Post-prandial lipaemia with the production of triglyceride rich lipoproteins (TGRL) results in enhanced oxidative stress and deterioration in endothelial function in non-insulin dependent diabetes. LM Evans, RA Anderson, J Graham, GR Ellis, JS Davies, SK Jackson, MP Frenneaux, A Rees. *Atherosclerosis* 1999 141 (1) 185.

Coagulation factors in hypopituitary adults with GH deficiency. LM Evans, JS Davies, A Rees, MF Scanlon. *Journal of endocrinology* 1998. 156 (Suppl): 25.

Elevated plasma homocysteine levels are associated with enhanced oxidative stress and endothelial dysfunction in hypopituitary patients with GHD. LM Evans, JS Davies, RA Anderson, SK Jackson, JC Smith, CL Morgan, I McDowell, A Rees, MF Scanlon. *Journal of Endocrinology* 1999. 160 (suppl) 22.

Pituitary apoplexy following combination chemotherapy. JS Davies, DA Rees, LM Evans, MF Scanlon. *Journal of Endocrinology* 156 (suppl): 26.

Growth hormone replacement therapy reduces oxidative stress in adult growth hormone deficiency (GHD). RA Anderson, LM Evans, JS Davies, GR Ellis, MJ Lewis, MP Frenneaux, A Rees. *Endocrine society, New Orleans*, 1998. P220

GH replacement therapy reduces oxidative stress and reverses endothelial dysfunction in adult hypopituitary patients with GHD. LM Evans, RA Anderson, JS Davies, GR Ellis, MP Frenneaux, MJ Lewis, SK Jackson, A Rees, MF Scanlon. *European Heart Journal* 1998(Suppl). P1001, 233.

The role of post-prandial lipaemia in the pathogenesis of atherosclerosis in NIDDM: Triglyceride rich lipoproteins and oxidative stress as possible mechanisms. LM Evans, RA Anderson, GR Ellis, JS Davies, MJ Lewis, MP Frenneaux, S Jackson, A Rees. P 867, *EASD* 1998.

Prevalence of psychiatric illness and associated activity for patients with hypopituitarism. AG Ogunko, C LL Morgan, JS Davies, LM Evans, MF Scanlon. 26th international symposium on GH and growth factors in *Endocrinology and metabolism*. Majorca 1998

Prevalence and inpatient activity for a population with hypopituitarism and growth hormone deficiency. JS Davies, C LL Morgan, AG Ogunko, LM Evans, MF Scanlon. 26th international symposium on GH and growth factors in *Endocrinology and metabolism*. Majorca 1998

Post-prandial lipaemia is associated with augmented free radical release in diabetics compared with healthy controls. *American College of Cardiology*. 1999. RA Anderson, LM Evans, GR Ellis, SK Jackson, MJ Lewis, A Rees, MP Frenneaux.

NIDDM subjects exhibit an increase in lipid peroxidation and augmented endothelial dysfunction in response to post-prandial lipaemia. *British cardiac society*. 1999. RA Anderson, LM Evans, GR Ellis, SK Jackson, MJ Lewis, A Rees, MP Frenneaux.



Contribution of two endothelial nitric oxide synthase gene (ec NOS) polymorphisms to vascular disease in type 2 diabetes. S Potter, LM Evans, K Mabe, A Thomas. Diabetic Medicine 2000, 17 (Suppl 1) P19.

The association between cardiovascular risk factors and macrovascular disease in type 2 diabetes. LM Evans, P McEwan, JR Peters, A Rees. British Hyperlipidaemia association. July 2000

A computer simulation of metabolism and clinical complications in type 2 diabetes. LM Evans, SR Hummel, A Bagust, PK Hopkinson, CJ Currie. EASD. September 2000.

Vitamin C therapy attenuates oxidative stress and restores endothelial function in young patients with familial hypercholesterolaemia. LM Evans, RA Anderson, GR Ellis, JC Smith, SK Jackson, MJ Lewis, JS Davies, A Rees, MP Frenneaux. Clinical Science. 2000; (10): 1382.

Insulin lispro attenuates postprandial lipaemia and improves endothelial function in type 2 diabetic patients irrespective of glycaemic control. Khan N, Evans LM, Anderson R, Morris K, Davies S, Rees A. American Diabetes Association 2001

Chronic Vitamin C therapy attenuates endothelial dysfunction associated with post-prandial lipaemia in type 2 diabetic patients. Khan N, Evans LM, Morris K, Smith J, Anderson R, Frenneaux MP, Rees A. American Diabetes Association. 2001

Pravastatin attenuates glycated protein and glucose induced free radical release in whole blood and a human monocyte cell line. Thomas AW, Morris K, Rees A, Davies S, Lazarus J, Evans LM. American Diabetes Association. 2001

PPAR- $\gamma$  antagonist: Possible therapy for thyroid eye disease. Starkey KJ, Davies JS, Evans LM, Luddgate M. American Thyroid Association 2001

Insulin Lispro therapy improves endothelial function, attenuates post-prandial lipaemia and reduces oxidative stress, irrespective of glycaemic control. Evans LM, Khan N, Anderson R, Morris K, Frenneaux MP, Rees A. Atherosclerosis 2001(159): 250.

The Pro-12-Ala mutation of PPAR-gamma receptor gene is associated with lower fasting plasma glucose and elevated total and non-HDL-Cholesterol levels in obese patients with type 2 diabetes. M Ahluwalia, LM Evans, A Rees, K Morris, S Davies, C Currie, A Thomas. Diabetes 2002 (Suppl 2) A263

Activation of the PPAR-gamma receptor influences vascular function by endothelium dependent and independent mechanisms. M Ahluwalia, LM Evans, A Rees, K Morris, S Davies, C Currie, A Thomas. Diabetes 2002 (Suppl 2) A166

Increased Augmentation Index in subjects with type 2 diabetes and cardiovascular disease. PM Underwood, IB Wilkinson, P McEwan, JS Davies, M Evans, A Rees, JR Cockcroft. Diabetes 2002 (Suppl 2) A173

PPAR-Gamma agonist attenuates TNF-alpha expression and release from human monocytes stimulated with glycated protein. M Ahluwalia, LM Evans, A Rees, K Morris, S Davies, C Currie, A Thomas. Diabetes 2002 (Suppl 2) A179

The relationship between glycated haemoglobin, leucocyte activation and endothelial damage in type 2 diabetes. RA Adams, SE Evans, AW Thomas, A Rees, M Evans. Diabetes 2002 (Suppl 2) A175

Endothelial dysfunction in adult offspring reared in a diabetic uterus. An embryo transfer experiment. JC Alcolado, D Lang, M Evans, R Gill-Randall. Association of physicians of Great Britain and Ireland. April 3rd 2003

Pioglitazone but not the specific ppa- agonist GW 745 down regulates glycated protein induced cyclooxygenase 2 expression in human monocytes P772 Diabetes 2003 suppl 1 vol 52 A180

Pioglitazone inhibits actin polymerisation in monocytes and polymorphic nuclear cells : A potential antithrombotic effect of TZD therapy. Thomas AW, Evans M, Morris K, Roberts A, Rees A. Diabetes

2003 suppl 1 vol 52 P 737 ( A172)

Folic acid and sepiapterin restores endothelial function in non-diabetic rat offspring from diabetic GK rat mothers following embryo transfer Evans M, Thomas AW, Lang D, Gill-Randall, Alcolado JC. Diabetes 2003 suppl 1 vol 52 P742 (A173)

Provision of secondary prevention following a myocardial infarction in subjects with and without diabetes Underwood P, Cozma L, Evans M, Beck P Diabetes 2003 suppl 1 vol 52 P726 A169.

Conjugated linoleic acid reduces glycated protein induced COX-2 expression and inflammatory cytokine release in human monocytes : A potential antiatherogenic role for polyunsaturated fatty acids. Morris K, Thet Lin L, Thomas AW, Evans M, Rees A. P760 (A177)

Owens D, Evans M, Carroll D, Keech M. Insulin glargine plus OHAs versus biphasic insulin in Type 2 diabetes – a cost comparison. Diabetes 2009; 58: Supp 1, A141

Evans M, Owens D, Carroll D, Keech M. Cost savings in Type 2 diabetes with insulin glargine compared with insulin detemir in the UK. Diabetes 2009; 58: Supp 1, A517

#### Book Chapters

Cardiovascular Disease and type 2 diabetes – Epidemiology aetiology and therapeutic advances. Evans M, Rees A. Year book in Dyslipidaemia 2004 (Martin Dunitz)

Therapeutic issues in type 2 diabetes. Evans M, Rees A. Year book in Dyslipidaemia 2004 (Martin Dunitz)

The International Textbook of Lipidology (2007). (Blackwell publishing)

Chapter 5 – Therapeutic approaches to lipid metabolism Evans LM

Chapter 6 – Diabetic Dyslipidaemia. Pathogenesis and Clinical Implications. Evans LM

Hot Topics in Diabetes (2007) (Blackwell Publishing)

Oral Hypoglycaemic therapy Peter R, Evans LM

# Brian Murray Frier



Curriculum Vitae

Brian Murray Frier

## PERSONAL INFORMATION

### Brian Murray Frier



BHF Centre for Cardiovascular Science, The Queen's Medical Research Institute, Scotland, UK

+44 131 447 1653 +44 7917 194651

[brian.frier@gmail.com](mailto:brian.frier@gmail.com)

Sex Male | Nationality British

## POSITION

### Honorary Professor of Diabetes

## WORK EXPERIENCE

2001-ongoing

#### Honorary Professor of Diabetes

BHF Centre for Cardiovascular Science, The Queen's Medical Research Institute, Scotland, UK

Higher University sector

1987-2012

#### Consultant Physician

Department of Diabetes, Royal Infirmary of Edinburgh, Edinburgh, University of Edinburgh, Scotland, UK

Healthcare sector

## EDUCATION AND TRAINING

1969 BSc Physiology (Honours, Class 1)

1972 MB. ChB

1981 MD

1974 MRCP (UK)

1984 FRCP (Edinburgh)

1986 FRCP (Glasgow)

University of Edinburgh

## ADDITIONAL INFORMATION

- Membership of learned Societies**
- Diabetes UK
  - American Diabetes Association
  - European Association for the Study of Diabetes
  - Association of Physicians of Great Britain & Ireland
  - Scottish Society of Physicians
  - Scottish Society for Experimental Medicine
  - Association of British Clinical Diabetologists
  - Caledonian Society for Endocrinology
- Named Lectureships**
- 1986 R.D. Lawrence Lecture, British Diabetic Association (Diabetes UK)
  - 1989 Honyman Gillespie Lecture, Edinburgh
  - 1997 Sydney Watson Smith Lecture, Royal College of Physicians of Edinburgh
  - 2004 Somogyi Award, Hungarian Diabetes Association
  - 2009 Banting Memorial Lecture, Diabetes
  - Invited speaker at major British (D-UK, ABCD) and international (ADA, EASD, IDF) conferences, and many other national and international scientific meetings.
- Visiting Professor**
- 1989 Maine Medical Centre, Portland, Maine, USA
  - 1996 VA Medical Centre, San Diego, University of California, USA
  - 2008 Garvan Institute, St Vincent's Hospital, Sydney; Canberra Hospital, Canberra, Australia
  - 2011 Mount Sinai Hospital, Toronto, Canada; University of Michigan, Ann Arbor, Michigan
- National Appointment**
- Chair (2001-2012) - Honorary Medical Advisory Panel on Driving and Diabetes to Secretary of State for Transport (UK); Panel member 1993-2012
  - Chair (2003-2006) - Diabetes Research in Scotland, Chief Scientist Office, Department of Health
  - Vice-President, Royal College of Physicians of Edinburgh (2008-2012); Council member 2004-12

## ANNEXES

### Bibliography

Original papers on hypoglycaemia in humans, complications and therapeutics of diabetes, plus editorials, review articles, and book chapters, principally on hypoglycaemia and diabetes (500 in total). Editor of *Diabetic Hypoglycemia* (on-line, free access, international e-journal), 2008-14

### Books

Co-Editor (with B.M. Fisher) '*Hypoglycaemia and Diabetes: Clinical and Physiological Aspects*' Edward Arnold, London (1993)

Co-Editor (with B.M. Fisher) '*Diabetes in Clinical Hypoglycaemia*' John Wiley & Sons, 1st Edition (1999); 2nd Edition (2007); Co-editors SR Heller, RJ McCrimmon 3rd Edition (2014)

Co-authored with M.W.J. Strachan, '*Insulin Therapy – A Pocket Guide*' Springer Verlag, London (2013)

*Diary Item*

June 23, 2015

# Stefano Genovese

## CURRICULUM VITAE



### INFORMAZIONI PERSONALI

Cognome	<b>GENOVESE</b>
Nome	<b>STEFANO</b>
Nazionalità	Italiana
Data di nascita	7 MARZO 1961
Indirizzo Privato	Via PIETRASANTA, 12 – 20141 MILANO (MI) - ITALIA
Telefono	+39 02 56808682
E-mail privato	st.genovese@gmail.com
Indirizzo Professionale Attuale	MULTIMEDICA IRCCS UO DI DIABETOLOGIA E MALATTIE METABOLICHE Via MILANESE, 300 – 20099 SESTO SAN GIOVANNI (MI) - ITALIA
Telefono Diretto	+39 335 7058511
Telefono Ambulatorio Diabetologia	+39 02 2420 9827/8/9
Fax	+39 02 2420 9837
E-mail	stefano.genovese@multimedica.it
Codice Fiscale	GNV SFN 61C07 F205N
Iscrizione all'Ordine dei Medici Chirurghi e degli Odontoiatri della Provincia di Milano	n. 26177 (12.02.1986)

### ESPERIENZA LAVORATIVA

- **1/5/2010 – ad oggi**
  - Nome-indirizzo del datore di lavoro Multimedica IRCCS, Via Milanese 300 -20099 Sesto San Giovanni (MI)
  - Tipo di impiego Responsabile della Unità Operativa Diabetologia e Malattie Metaboliche.
  - Principali mansioni e responsabilità Responsabile dell'Area di Diabetologia e Malattie Metaboliche Dipartimento Cardiovascolare e Metabolico del Gruppo Multimедica
- **1/7/2013 – ad oggi**
  - Nome-indirizzo del datore di lavoro Multimedica Castellanza, Via Piemonte, 70 – 21053 Castellanza (VA)
  - Tipo di impiego Responsabile del Servizio Ambulatoriale di Diabetologia ed Endocrinologia
  - Principali mansioni e responsabilità Responsabile dell'Area di Diabetologia e Malattie Metaboliche Dipartimento Cardiovascolare e Metabolico del Gruppo Multimедica
- **1/7/2011 – 1/7/2013**
  - Nome-indirizzo del datore di lavoro Multimedica Castellanza, Via Piemonte, 70 – 21053 Castellanza (VA)
  - Tipo di impiego Responsabile della Unità Operativa Medicina Generale – Diabetologia
  - Principali mansioni e responsabilità Responsabile dell'Area di Diabetologia e Malattie Metaboliche Dipartimento Cardiovascolare e Metabolico del Gruppo Multimедica
- **1997 – 30/4/2010**
  - Nome-indirizzo del datore di lavoro Istituto Clinico Humanitas IRCCS, Via Manzoni 56 -20089 Rozzano (MI)
  - Tipo di impiego Aiuto della Unità Operativa (a direzione universitaria) di Endocrinologia e Diabetologia.
  - Principali mansioni e responsabilità Responsabile di Diabetologia

- **Novembre 1999 – Gennaio 2000**
  - Nome-indirizzo del datore di lavoro Istituto Clinico Humanitas, Via Manzoni 56 -20089 Rozzano (MI)
  - Principali mansioni e responsabilità Responsabile Ad Interim della Unità Operativa di Endocrinologia e Diabetologia
  - **1996 – 1997**
  - Nome-indirizzo del datore di lavoro Istituto Clinico Humanitas, Via Manzoni 56 -20089 Rozzano (MI)
  - Tipo di impiego Aiuto della Unità Operativa di Medicina Generale.
  - Principali mansioni e responsabilità Responsabile di Diabetologia
  - **1992 – 1996**
  - Nome-indirizzo del datore di lavoro Istituto Scientifico Ospedale San Raffaele, Via Olgettina 60 -20089 Milano (MI)
  - Tipo di impiego Assistente medico ricercatore presso la Divisione di Medicina 1 - Cattedra di Clinica Medica, Università degli Studi di Milano.
  - Principali mansioni e responsabilità Attività clinica ambulatoriale e di reparto. Attività di ricerca sulla eziopatogenesi del Diabete Mellito di tipo 1
  - **1991 – 1992**
  - Nome-indirizzo del datore di lavoro The London Hospital Medical College, London, U.K.
  - Tipo di impiego Research Fellow presso il Department of Immunology,
  - Principali mansioni e responsabilità Attività di ricerca sulla eziopatogenesi del Diabete Mellito di tipo 1
  - **1990 – 1991**
  - Nome-indirizzo del datore di lavoro Saint Bartholomew's Hospital, London, U.K.
  - Tipo di impiego Honorary Clinical Assistant presso il Department of Diabetes and Metabolism
  - Principali mansioni e responsabilità Attività di ricerca sulla eziopatogenesi del Diabete Mellito di tipo 1
  - **1990 – 1991**
  - Nome-indirizzo del datore di lavoro University College and Middlesex School of Medicine, London, U.K.
  - Tipo di impiego Research Fellow presso il Department of Immunology
  - Principali mansioni e responsabilità Attività di ricerca sulla eziopatogenesi del Diabete Mellito di tipo 1
  - **1988 – 1992**
  - Nome-indirizzo del datore di lavoro Istituto Scientifico Ospedale San Raffaele, Via Olgettina 60 -20089 Milano (MI)
  - Tipo di impiego Borsista ricercatore presso la Divisione di Medicina 1 - Cattedra di Clinica Medica, Università degli Studi di Milano.
  - Principali mansioni e responsabilità Attività di ricerca sulla eziopatogenesi del Diabete Mellito di tipo 1
  - **1986 – 1987**
  - Nome-indirizzo del datore di lavoro Ospedale Militare Principale di Milano
  - Tipo di impiego Servizio di Leva con il grado di Sottotenente Medico
  - Principali mansioni e responsabilità Assistente di Reparto
- ATTIVITÀ DIDATTICA**
- **Dall'Anno Accademico 2012-2013**
  - Tipologia di insegnamento Titolare dell'insegnamento di Patologia Generale nel Corso Diploma di Laurea in Infermieristica, dell'Università degli Studi di Milano, nella sede dell'Ospedale San Giuseppe – Gruppo Multimedica.
  - **Dall'Anno Accademico 2006-2007 all'Anno Accademico 2009-2010**
  - Tipologia di insegnamento Titolare dell'insegnamento di Endocrinologia nel Corso Diploma di Laurea in Infermieristica, dell'Università degli Studi di Milano, nella sede dell'Istituto Clinico Humanitas.
  - **Dall'Anno Accademico 2006-2007 all'Anno Accademico 2009-2010**
  - Tipologia di insegnamento Contratto di Insegnamento per le esigenze del Corso di Laurea Magistrale in Medicina e Chirurgia della Università degli Studi di Milano, nel corso Integrato di Semeiotica e Sistemica II



c/o Istituto Clinico Humanitas (Settore Scientifico Disciplinare MED/13 Endocrinologia).

• **Anno Accademico 2005-2006**

- Tipologia di insegnamento

Contratto di Insegnamento per le esigenze del Corso di Laurea Magistrale in Medicina e Chirurgia della Università degli Studi di Milano, nel corso Integrato di Semeiotica e Sistemica II c/o Istituto Clinico Humanitas (Settore Scientifico Disciplinare MED/09 Medicina Interna).

**ISTRUZIONE E FORMAZIONE**

• **Anni Accademici 1998-99/2002-03**

- Nome e tipo di istituto di istruzione

Scuola di Specializzazione in Endocrinologia e Malattie del Ricambio, Università degli Studi di Milano

- Qualifica conseguita

Specialista in Endocrinologia e Malattie del Ricambio

- Titolo della tesi

"Il diabete mellito di Tipo 1 (immuno-mediato) ad insorgenza in età adulta. Prevalenza e caratteristiche cliniche di un numeroso campione di pazienti Italiani" – 3 Marzo 2004.

• **Anni Accademici 1985-86/1989-90**

- Nome e tipo di istituto di istruzione

Scuola di Specializzazione in Medicina Interna, Università degli Studi di Milano

- Qualifica conseguita

Specialista in Medicina Interna

- Titolo della tesi

"Markers immunosierologici di diabete di tipo 1: analisi trasversale di uno studio familiare" – 16 Luglio 1990

• **Novembre 1985**

- Nome e tipo di istituto di formazione

Università degli Studi di Milano

- Qualifica

Abilitazione all'esercizio della professione di Medico Chirurgo

• **Anni Accademici 1979-80/1984-85**

- Nome e tipo di istituto di istruzione

Corso di Laurea in Medicina e Chirurgia, Università degli Studi di Milano

- Qualifica conseguita

Dottore in Medicina e Chirurgia

- Titolo della tesi

"Acido folico plasmatico ed eritrocitario nelle epatopatie alcoliche" – 17 Luglio 1985 *Cum Laude*

• **Anno scolastico 1978-79**

- Nome e tipo di istituto di istruzione

Liceo Ginnasio "G. Berchet", Milano

- Qualifica conseguita

Maturità Classica

**CAPACITÀ E COMPETENZE**

ATTIVITÀ CLINICA  
(ALLEGATO 1 – RICERCA  
CLINICA)

Attività di reparto ed ambulatoriale in Diabetologia, Endocrinologia, Malattie Metaboliche, Dietologia e Medicina Interna.

Principal Investigator in trial clinici secondo GCP (n° 35 dal 1998 ad oggi - studi di fase IIa, IIIa e IIIb, IV e osservazionali). In 4 studi ha svolto anche il ruolo di Coordinatore Nazionale (tre studi di fase III ed uno studio osservazionale).

ARGOMENTI DI RICERCA E  
STUDIO

Autoimmunità del sistema endocrino:

- eziopatogenesi del diabete di tipo 1 e di altre endocrinopatie autoimmuni;
- identificazione e caratterizzazione degli antigeni bersaglio di processi autoimmuni;
- metodologie delle determinazioni autoanticorpali.

Studi di popolazione e identificazione di marcatori per la predizione del diabete di tipo 1 e per la predizione e diagnosi precoce del diabete di tipo 2.

La terapia del diabete di tipo 2

Le complicanze cardiovascolari del diabete mellito con particolare riferimento allo scompenso cardiaco.

LETTURE, CONFERENZE E MODERAZIONI SU INVITO	Relatore e Moderatore in numerosi congressi, convegni o seminari nazionali e internazionali
ATTIVITÀ COME EDITOR E REFEREE DI RIVISTE SCIENTIFICHE	<p>Advisory Board di Acta Diabetologica</p> <p>Referee per le seguenti riviste</p> <ul style="list-style-type: none"> <li>- Acta Diabetologica</li> <li>- Diabetes Technology and Therapeutics</li> <li>- Diabetes and Metabolism Research and Reviews</li> <li>- Diabetic Medicine</li> <li>- Diabetologia</li> <li>- European Journal of Endocrinology</li> <li>- Journal of Autoimmunity</li> <li>- Journal of Endocrinological Investigation</li> </ul>
SOCIETÀ SCIENTIFICHE	<p>SOCIETÀ ITALIANA DI DIABETOLOGIA (SID)</p> <ul style="list-style-type: none"> <li>- Socio ordinario</li> <li>- 2001 - 2004 Membro del Comitato di Coordinamento del Gruppo di Studio "Diabete di tipo 1"</li> <li>- Dal 2002 al 2006 Membro del Comitato Scientifico</li> <li>- Dal 2005 Membro del Comitato Scientifico NIRAD</li> </ul> <p>ASSOCIAZIONE MEDICI DIABETOLOGI (AMD)</p> <ul style="list-style-type: none"> <li>- Socio ordinario</li> <li>- Dal 2010 Tutor Regionale per gli Annali AMD</li> <li>- Dal 2011 Membro del Centro Studi e Ricerche (CSR)</li> <li>- Dal 2013 Membro del Consiglio d'Amministrazione FondAMD Onlus</li> </ul> <p>EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD)</p> <ul style="list-style-type: none"> <li>- Socio ordinario</li> </ul>
PREMI	<p>Premio della Società Italiana di Diabetologia - Sezione Regionale Lombarda (Bergamo, 11 novembre 1995)</p> <p>Premio 'Boehringer Mannheim-Italia', 14° Congresso della Società Italiana di Diabetologia (Genova, 17-20 maggio 1992).</p> <p>Premio di Studio della 'Fondazione Emilio Trabucchi', Dipartimento di Farmacologia, Università degli Studi di Milano (1986).</p>
PUBBLICAZIONI *(ALLEGATO 2)	<p><b>Autore o coautore in:</b></p> <ul style="list-style-type: none"> <li>- 37 articoli originali su riviste internazionali censite, di cui: 29 originali come autore o co-autore principale, 7 originali in collaborazione e 1 rassegna.</li> </ul>
MADRELINGUA	<b>ITALIANA</b>
ALTRE LINGUA	<p><b>INGLESE</b></p> <ul style="list-style-type: none"> <li>• Capacità di lettura Ottima</li> <li>• Capacità di scrittura Ottima</li> <li>• Capacità di espressione orale Ottima</li> </ul> <p><b>FRANCESE</b></p> <ul style="list-style-type: none"> <li>• Capacità di lettura Ottima</li> <li>• Capacità di scrittura Buona</li> <li>• Capacità di espressione orale Ottima</li> </ul>

Milano, 01/09/2013



Dott. Stefano Genovese

*Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196: "Codice in materia di protezione dei dati personali".*

# Jean François Yale

## PERSONAL INFORMATION

Jean François Yale



📍 McGill University, Medica Department, Montreal, Quebec H3A 2R7

☎ Tel: (514) 843 1665

✉ [JEAN-FRANCOIS.YALE@McGILL.CA](mailto:JEAN-FRANCOIS.YALE@McGILL.CA)

Sex Male | Nationality Canadian

## POSITION

Professor in the Department of Medicine and Nutrition and Food Science Centre

## WORK EXPERIENCE

2001-present Professor in the Department of Medicine and Nutrition and Food Science Centre  
McGill University

Higher Education sector

1991-2008 Director,  
Metabolic Day Centre, Royal Victoria Hospital

Healthcare sector

## EDUCATION AND TRAINING

1975-1979 M.D.  
Université de Sherbrooke

1979-1983 CSPQ  
Université de Montréal Endocrinology

1983-1985 Post-Doctoral Fellow  
Crabtree Laboratories, McGill Nutrition Centre, McGill University, Montreal, Quebec, Canada.

## ADDITIONAL INFORMATION

Professional and/or learned societies

Chairperson 1992-1994:  
• Clinical and Scientific Section  
• Canadian Diabetes Association

Steering Committee 09/1996 –ongoing:  
• Clinical Practice Guidelines for the Management of Diabetes in Canada

## ANNEXES

PUBLICATIONS: 115

Examples:

Yale JF, Valiquett TR, Ghazzi MN et al. The Effect of a Thiazolidinedione Drug, Troglitazone, on Glycaemia in Patients with Type 2 Diabetes Mellitus Poorly Controlled with Sulfonylurea and Metformin. *Annals of Internal Medicine* 134: 737- 745, 2001

Kalergis M, Nadeau J, Pacaud D, Yared Z, Yale JF. Accuracy and reliability of reporting self-monitoring of blood glucose results in adults with type 1 and type 2 diabetes. *Canadian Journal of Diabetes* 30(3):241-247, 2006.

REVIEWS: 80

Examples:

Yale JF, Scott F. and Marliss EB. Lessons from Animal Diabetes: The BB Rat, In: *Diabetes Prediction, Prevention and Genetic Counselling* (ed) Palmer JP, John Wiley + Sons, Chapter 19, pp 318-348, 1996.

Yale JF. Hypoglycaemia (Chapter 20). IN : *Evidence-based Diabetes Care*. Gerstein HC and Haynes RB, Editors. B.C. Decker Inc, Publisher, Hamilton, Ontario, Canada. 2001.

ABSTRACTS: 194

Jean-François Yale  
24/6/2015

# Edoardo Gronda



Curriculum Vitae et Studiorum

Edoardo Gronda M.D.

## PERSONAL INFORMATION

Edoardo Gronda M.D.



Via Cernaia 11, 20121-Milan  
3474207014  
edogronda@icloud.com  
<https://www.researchgate.net/profile/EdoardoGronda/stats>  
Sex Male | Date of birth 20/11/1951 | Nationality Italian

## PREFERRED POSITION

Expert in Care of complex patients with Cardiac Insufficiency

## WORK EXPERIENCE

- From 1<sup>st</sup> July 2007-now Director of Cardiology Division  
IRCCS Multimedica, Sesto San Giovanni (MI)
- From 2000-June 2009 *Business or sector* Clinical Cardiology  
Director of Clinical Cardiology & Heart Failure Unit  
Istituto clinico Humanitas, IRCCS, Milan
- From 1996-1999 *Business or sector* Clinical Cardiology  
Medical Director of "Heart Transplant Program"  
Dipartimento Cardiologico e Cardiochirurgico Ospedale regionale "Ca' Granda", Milan
- Business or sector* Clinical Cardiology

## EDUCATION AND TRAINING

- In 1986 Clinical Director  
Qualified by the Italian National Board
- 1984, June-July Internship on Cardiac Transplant  
London Ontario University
- In 1976, 26<sup>th</sup> January Qualified by "Educational Commission for Foreign Medical Graduates" (E.C.F.M.G)
- In 1978, 17<sup>th</sup> July Cardiology Fellowship  
Ospedale Maggiore Policlinico, Università degli Studi di Milano
- In 1976, 14<sup>th</sup> June Graduated cum Laude MD  
Università degli Studi di Milano

## PERSONAL SKILLS

Mother tongue Italian

Other language

English

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	B2	B2	B2	B2

Common European Framework of Reference for Languages (CEFR)

Communication skills	<ul style="list-style-type: none"><li>■ Good communication skills gained through experiences with patients and their families</li><li>■ Good didactic skills gained through participation to international medical congress, as Relator and Moderator</li></ul>
Organisational / managerial skills	<ul style="list-style-type: none"><li>■ Leadership, acquired through management of hospital units</li><li>■ Team building</li><li>■ In basket activity and goal-setting</li></ul>
Job-related skills	<ul style="list-style-type: none"><li>■ Good scientific writing skills gained through continuous academic writing activity</li><li>■ Great interest in research and clinical study</li></ul>
Computer skills	<ul style="list-style-type: none"><li>■ Good command of Microsoft Office™ tools, especially Word and PowerPoint</li></ul>
In free time	<ul style="list-style-type: none"><li>■ Sport (swimming, cycling, kayak)</li><li>■ Reading of historical essays</li></ul>
Driving licence	B

## ADDITIONAL INFORMATION

Academic Appointments 2007-now	Teaching Professor of Cardiology at "Scuola di Specializzazione di Cardiologia, Università degli Studi di Firenze" Directed by Professor Luigi Padeletti Careggi Hospital IRCCS
1998 - 2000	Teaching Professor at "Scuola di Specializzazione di Medicina Interna II, Università degli Studi di Milano" headed by Professor Angelo Agostoni Maggiore Policlinico Hospital
Publications	91 among Articles and Report Studies. For further information, please read the Dossier attached
Studies and Projects	Principal Investigator in Bayer Mariner Study on RIVAROXOBAN Treatment on patients with thromboembolic risk 1998-1999, Principal Investigator to Phase 2 Study for Dose Finding Research, OMAPRATILAT Drug
Honours and awards	In 1981, Clinical Research Awards "Furio Cicogna" (ex aequo), Associazione "Amici del Centro Angelo De Gasperis" dell'Ospedale Generale Regionale Ca' Granda Milano Niguarda
Editorial/Reviewer Memberships	2004-2005, Reviewer European Heart failure Guidelines 2000, Guest Editor Journal of Heart and Lung Transplantation Vol 19 Number 8S 1999-2002, Italian Heart Journal 1995-1999, Giornale Italiano di Cardiologia and Journal of Heart and Lung Transplantation
Manuscript Reviewer for	Giornale Italiano di Cardiologia European Heart Failure Journal The Journal of Cardiovascular Medicine The Journal of Heart and Lung Transplantation Circulation
Professional and Scientific Organization Membership	Fellow of the European society of Cardiology Fellow ANMCO (Associazione Nazionale Cardiologi Ospedalieri) Co-chair person of Heart Failure Council in International Society for Heart and Lung Transplantation

**Membership in national and international scientific Program Committee**

13-14 April 2007, "Heart Failure & Co." International Symposium Istituto Clinico Humanitas, Rozzano, Milano  
28-29 April 2006, "Heart failure prevention and management from drugs to devices", Centro Congressi Convitto della Calza, Firenze International Symposium VI edition  
1-2 April 2005, "Heart failure prevention and management from drugs to devices" International Symposium V edition, Centro Congressi "Magazzini del Cotone", Genova  
2004, San Francisco, XXIV Scientific Meeting & Scientific Session of international Society for Heart & Lung Transplantation  
1998, Chicago, XVIII Scientific Meeting & Scientific Session of international Society for Heart & Lung Transplantation  
1997, London, XVII Scientific Meeting & Scientific Session of international Society for Heart & Lung Transplantation  
1996, New York, XVI Scientific Meeting & Scientific Session of international Society for Heart & Lung Transplantation

**Advisory Board Membership**

SORIN Neuro-modulation Advisory Board  
CVRx Barostim Advisory Board  
Novartis Telemedicine Advisory Board  
BIOTRONIK Advisory Board for HF management

**Personal Data**

I hereby authorize the use of my personal details solely for circulation within the company in relation to the Italian Legislative Decree n° 196/2003

**ANNEXES**

Dossier of Publications and Research, Clinical Studies and Investigations

Edoardo Gronda

Sesto San Giovanni, 1/05/2015





# Jørgen Rungby



Curriculum Vitae

Jørgen Rungby

## PERSONAL INFORMATION

Jørgen Rungby



GA Hagemanns Vej 27, DK-3070, Snekkersten  
+4587167569/+4521682430/+4539777539  
[jr@biomed.au.dk](mailto:jr@biomed.au.dk)

Sex Male | Date of birth 24/10/1957 | Nationality Danish

## POSITION

Chief Physician

## WORK EXPERIENCE

Ongoing

Chief Physician, Dept. Endocrinology and Centre for Diabetes Research  
Gentofte University Hospital, DK.  
Professor of Clinical Pharmacology  
University of Aarhus, DK.  
Clinical lecturer, Clinical Pharmacology  
University of CPH, DK

1996

Chief Physician in Endocrinology and Diabetes  
University Departments in Aarhus and Copenhagen, DK  
Healthcare sector

## EDUCATION AND TRAINING

1984

MD

1990

DMsc

1994

Specialised in Endocrinology and Diabetes

1995

Internal Medicine

## ADDITIONAL INFORMATION

- Administrative**
- Head of Dept, Silkeborg Hospital, 5 years (>300 employees)
  - Head of Endocrinology, Aarhus University Hospital, 7 years (>500 employees)
- Academic**
- Presently supervising 4 Ph.D. students, main supervisor 2, Aarhus University and Copenhagen University, previously 24
  - Full professor of Clinical Pharmacology, University of Aarhus 2006-2014
  - Teaching experience is in Clinical Medicine, Pharmacology, Endocrinology and Diabetes as a lecturer and professor. Courses and lectures have been at pre- and Postgraduate levels, nationally and abroad
  - Frequent reviews for international journals, including the Lancet, American J Physiol, Basal and Clinical Pharmacology and Toxicology, Diabetes, JAMA, Diabetologia, JCEM.
- Research Administration**
- Evaluation Committee, National Medical Research Council, Singapore Ministry of Health, 2014-
  - Evaluation Committee, The Faroese Research Council, 2014-
  - Evaluation Committee, Estonian Research Council, 2014-
  - Evaluation Committee, Alzheimer's Disease Foundation Research Programme 2010-
  - Chair of the Research Committee, Danish Medical Association, 2007-14
  - Member, LOC, ECE (European Congress of Endocrinology), CPH, 2013
  - Board member, Yde's Foundation, 2007-
  - Board member, Danish Centre for Strategic Research in Type 2 Diabetes, [www.dd2.nu](http://www.dd2.nu)
  - Board member, Lucamp project, [www.lucamp.org](http://www.lucamp.org)
  - Chair, Danish Society for Endocrinology, 2002-6
  - Chairmanships at international meetings including the EASD 2008-
  - Member, Medical Council, Danish Diabetes Organisation
  - Member, National Diabetes Group, Danish Health Board
  - National or principal investigator in more than 30 phase 1-4 studies
  - Since 1996 advisor to several pharmaceutical companies, national and international.
  - Censured more than 25 PhDs / DMSc theses, 3 Professorships and a number of lectorates
- Current International Collaborations**
- University of Grenoble, France: ZnT8 and Diabetes
  - University of Southampton, UK and Profil, CA, USA: Pharmacoepidemiology of Diabetes
  - Free University of Brussels, Laboratory of Experimental Medicine, Belgium: Genome and Beta cells
  - University of Melbourne: ZnT3, Alzheimers and Diabetes
  - Imperial Coll, London: Neuroinflammation
  - Lieber Inst, Johns Hopkins, Baltimore: Genes and brain metabolism

## ANNEXES

### Publications

165 (2015 MAY) publications, not including book chapters and abstracts ~3400 citations, H-index 31

 Digitalt signeret af Jørgen Rungby  
 DN: cn=Jørgen Rungby, o, ou, email=jr@farm.au.dk, c=DK  
 Dato: 2015.06.24 17:11:40 +01'00'

# Guntram Schernthaler



Curriculum Vitae

Guntram Schernthaler

## PERSONAL INFORMATION

Guntram Schernthaler



📍 Medical University of Vienna, Austria

✉ [guntram.schernthaler@meduniwien.ac.at](mailto:guntram.schernthaler@meduniwien.ac.at)

Sex Male | Nationality Austrian

## POSITION

Professor of Medicine

## WORK EXPERIENCE

- 1987-ongoing Professor of Medicine,  
Medical University of Vienna
- 1987-1988 Head of the Division of Diabetes & Endocrinology, Dept Medicine II,  
Medical University of Vienna
- 1988-2013 Director of the Department of Medicine I (Diabetes, Endocrinology & Oncology)  
Rudolfstiftung Hospital, Vienna, Austria  
  
Healthcare sector
- 1988-1991 Council Member of the European Society for Clinical Investigation  
1991 Vice-President of the European Society for Clinical Investigation
- 1994-1997 Council Member of the European Diabetes Association  
1996 President of the 32nd European Diabetes Congress – 32nd Annual Meeting of the  
European Diabetes Association (EASD)  
Vienna, Austria

## EDUCATION AND TRAINING

1972-ongoing M.D

---

#### ADDITIONAL INFORMATION

Research Work	More than 350 papers published in leading Journals (Lancet, NEJM, Am J Medicine, Diabetes, JCEM, Diabetes Care, Diabetologia, Hypertension, JASN, ATVB, Atherosclerosis, Cancer, Internat.J.Obesity), are listed in the PubMed. According to the Citation Index of Web of Science ® his papers were cited more than 10.000 fold and his h-index is 45. His total impact factor is above 2000
International Scientific Co-operations and Publications	More than 40 Universities in Europe, USA, Australia, Canada, Japan, Brazil
Invited Lectures	Invited lectures were presented at many Annual Meetings of the following International Societies including: ADA, EASD, EDTA/ERA, IDF, European Society of Hypertension, European Society of Endocrinology, European Society of Obesity, International Society of Kidney Diseases, International Society of Cardiology, Chinese Society of Diabetes, CODHY International. Sept 2014: Invited Lecture at the Celebration Meeting of the 50th Anniversary of the EASD March 2015: Max Perutz Nobel Prize Memorial Lecture at the University of Cambridge

---

#### ANNEXES

##### Awards, Prizes, Medals

- 1982 Bertram Award of the German Diabetes Association
- 1997 Albert Renold Medal of the European Association for the Study of Diabetes (EASD)
- 2013 Honorary Member of the Austrian Diabetes Association
- 2014 Honorary Member of the German Diabetes Association
- 2015 Honorary Member of the Hungarian Diabetes Association

*L. Perutz ~ June 24, 2015*